Please ensure Javascript is enabled for purposes of website accessibility

UMB, MedImmune agree to collaborate

The University of Maryland, Baltimore and MedImmune Inc., of Gaithersburg, a subsidiary of British drug maker AstraZeneca PLC, announced they have entered into a five-year, $6 million agreement to work on novel bioscience research in Maryland.

Under the agreement, MedImmune will contribute at least $5 million and UMB at least $1 million in funding.

Scientists from both entities will collaborate on joint research projects, and provide opportunities for scientific exchange and educational training.

The University of Maryland, College Park and University of Maryland, Baltimore County will be integral members of the collaboration, along with the Maryland Department of Business and Economic Development.